Biosimilar competition continues to build in the U.S., with the FDA approving a second Neupogen (filgrastim, Amgen Inc.) biosimilar. New York-based Pfizer Inc. announced the approval Friday of its Nivestym (filgrastim-aafi) for all the eligible indications of the reference product.